Experiments preventing the degradation of CYP2E1 in mice by ablation of E3 ubiquitin ligase have demonstrated that the elevation of CYP2E1 alone in this model is insufficient to induce NASH. This evidence concerns the gene CYP2E1 and metabolic dysfunction-associated steatohepatitis.